Procept BioRobotics has raised $118 million in an equity round. The Redwood Shores, Calif.-based company plans to use the funding on the commercialization of its Aquablation robotic prostate surgery for benign prostate hyperplasia. Procept said new backer Viking Global Investors led the round, joined by Perceptive Advisors and existing investors including CPMG. The Aquablation treatment…
Procept BioRobotics said today that it won de novo clearance from the FDA for its Aquabeam device for treating benign prostate hyperplasia, saying it plans to have the device on the U.S. market early next year. Redwood Shores, Calif.-based Procept said the federal safety watchdog used the 181-patient Water study to inform its decision. The trial, comparing Aquablation…
